|1.||Lin, Yu-Min: 2 articles (02/2006 - 08/2004)|
|2.||Yeh, Chi-Hsiao: 2 articles (02/2006 - 08/2004)|
|3.||Zhang, Zhong-Ming: 2 articles (06/2004 - 11/2003)|
|4.||Xu, Peng-Cheng: 2 articles (06/2004 - 11/2003)|
|5.||Zhang, Yu-Cai: 2 articles (06/2004 - 11/2003)|
|6.||Zhu, Shan-Shan: 2 articles (06/2004 - 11/2003)|
|7.||Fan, Jian-Wei: 2 articles (06/2004 - 11/2003)|
|8.||Zeng, Yin-Ming: 2 articles (06/2004 - 11/2003)|
|9.||Lee, Chieh-Hung: 1 article (02/2006)|
|10.||Chen, Tzu-Ping: 1 article (02/2006)|
09/01/1989 - "This study was designed to test the hypothesis that asanguineous reperfusion with a standard crystalloid cardioplegic solution results in improved myocardial salvage after a period of global ischemia. "
08/01/2004 - "Twenty-four anesthetized dogs supported by total vented bypass were divided evenly into 4 groups (n = 6) and subjected to 60 minutes of hypothermic ischemia followed by 4 degrees C multidose crystalloid cardioplegic solution infusion. "
02/01/1998 - "Ischemia was induced by crystalloid cardioplegic solution at 4, 18, 30, and 34 degrees C for 120 min, respectively. "
11/01/1994 - "Thirty-six isolated blood-perfused hearts from newborn rabbits (age range, birth to 2 days) were subjected to 2 hours of cold global ischemia (15 degrees C), with an initial infusion of cold crystalloid cardioplegic solution, followed by 30 minutes of reperfusion (37 degrees C). "
05/01/1991 - "To examine the effect of initial coronary reperfusion pressure on endothelial function, we subjected 16 isolated perfused neonatal lamb hearts to 2 hours of ischemia with potassium cardioplegic solution followed by reperfusion for 1 hour. "
|2.||Heart Arrest (Cardiac Arrest)
01/01/1996 - "We made an investigation whether coronary dilation just prior to induction of cardiac arrest by aortic clamping and infusion of crystalloid cardioplegic solution would influence cardioprotection. "
04/01/1994 - "The aim was to determine the metabolic consequence of increasing the osmolality of a crystalloid cardioplegic solution during periods of cardiac arrest. "
03/01/1993 - "Thirty-five isolated rabbit hearts were subjected to 60 minutes of storage after cardiac arrest with high K+ crystalloid cardioplegic solution at 5 degrees C. "
09/01/1992 - "Maintenance of continuous aerobic metabolism during surgical cardiac arrest would require frequent administration of oxygenated crystalloid cardioplegic solution."
02/01/2006 - "PARP inhibitor-supplemented crystalloid cardioplegic solution diminished postischemic cardiomyocytic apoptosis and ROS-mediated injuries after global cardiac arrest under CPB, possibly via inhibiting both caspase-dependent and -independent apoptotic pathways, which also preserved postischemic myocardial contractility."
|3.||Myocardial Ischemia (Ischemic Heart Diseases)
11/01/1989 - "Hypothermic global myocardial ischemia was maintained for 90 minutes with intermittent crystalloid cardioplegic solution. "
05/01/1992 - "We evaluated the efficacy of verapamil, a calcium-channel blocking agent, as an adjunct to standard crystalloid cardioplegic solution in animals with left ventricular hypertrophy subjected to myocardial ischemia during cardiopulmonary bypass. "
01/01/1992 - "Evaluation of the survival and performance of each graft after 24 h and extent of tissue necroses indicated that the given standardly produced SFH variant ensured reproducible heart preservation from ischemic and reperfusion injury similarly as did the renown crystalloid cardioplegic solution CUSTODIOL."
05/01/1985 - "These findings indicate that significant buffering capacity (similar to that of blood) in a crystalloid cardioplegic solution can be effective in preserving myocardial adenosine triphosphate stores, improving postarrest contractile function, and minimizing myocardial necrosis, provided the combination of high extracellular potassium and high pH levels is avoided."
|5.||Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
|3.||Calcium Channels (Calcium Channel)
|6.||Adenosine Triphosphate (ATP)
|10.||Endothelium-Dependent Relaxing Factors (Endothelium Derived Relaxing Factor)
|1.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|3.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)